2023
Eligibility for Cardiovascular Risk Reduction Therapy in the United States Based on SELECT Trial Criteria: Insights From the National Health and Nutrition Examination Survey
Lu Y, Liu Y, Jastreboff A, Khera R, Ndumele C, Rodriguez F, Watson K, Krumholz H. Eligibility for Cardiovascular Risk Reduction Therapy in the United States Based on SELECT Trial Criteria: Insights From the National Health and Nutrition Examination Survey. Circulation Cardiovascular Quality And Outcomes 2023, 17: e010640. PMID: 37950677, PMCID: PMC10782930, DOI: 10.1161/circoutcomes.123.010640.Peer-Reviewed Original Research
2022
Contemporary National Patterns of Eligibility and Use of Novel Lipid‐Lowering Therapies in the United States
Shen M, Nargesi A, Nasir K, Bhatt DL, Khera R. Contemporary National Patterns of Eligibility and Use of Novel Lipid‐Lowering Therapies in the United States. Journal Of The American Heart Association 2022, 11: e026075. PMID: 36102276, PMCID: PMC9683659, DOI: 10.1161/jaha.122.026075.Peer-Reviewed Original ResearchConceptsLipid-lowering therapyIcosapent ethylCardiology/American Heart Association (ACC/AHA) guideline recommendationsNutrition Examination Survey dataAddition of ezetimibeUse of statinsClinical practice guidelinesCurrent statin usePopulation health outcomesConclusions SixCardiovascular outcomesStatin useClinical profileGuideline recommendationsLipid profileNational HealthPCSK9iNovel therapiesNovel agentsPractice guidelinesUS adultsAmerican CollegeStatinsHealth outcomesTherapy
2021
Repeated cross-sectional analysis of hydroxychloroquine deimplementation in the AHA COVID-19 CVD Registry
Bradley SM, Emmons-Bell S, Mutharasan RK, Rodriguez F, Gupta D, Roth G, Gluckman TJ, Shah RU, Wang TY, Khera R, Peterson PN, Das S. Repeated cross-sectional analysis of hydroxychloroquine deimplementation in the AHA COVID-19 CVD Registry. Scientific Reports 2021, 11: 15097. PMID: 34302004, PMCID: PMC8302649, DOI: 10.1038/s41598-021-94203-7.Peer-Reviewed Original ResearchConceptsCOVID-19Use of hydroxychloroquineActive COVID-19Cross-sectional analysisRandomized trialsIneffective therapyNational registryMedian useClinical careClinical informationDeimplementationU.S. hospitalsOverall proportionLittle dataHydroxychloroquineFurther studiesPatientsRegistryTherapyHospitalTrialsCare